Murat Kalayoglu - Oct 11, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Murat Kalayoglu
Stock symbol
RNAC
Transactions as of
Oct 11, 2024
Transactions value $
$0
Form type
4
Date filed
10/15/2024, 04:53 PM
Previous filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Options Exercise +1.52M +50% 4.56M Oct 11, 2024 by trust F1, F2
holding RNAC Common Stock 506K Oct 11, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Series A Non-Voting Convertible Preferred Stock Options Exercise -45.6K -44.68% 56.4K Oct 11, 2024 Common Stock 1.52M by trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 11, 2024, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.
F2 Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust.
F3 On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.